ACAD vs ALKS
ACAD: Acadia Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for CNS disorders and rare diseases. ALKS: Alkermes is a neuroscience-focused biopharmaceutical company developing and commercializing therapeutic treatments for complex neurological and psychiatric disorders.
Side-by-side fundamentals
| Metric | ACAD | ALKS | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $25.87 | $52.73 | |
| Market cap as of 2026-08-03 | $4.4B | $8.8B | |
| P/E as of 2026-08-03 | 11.82 | 53.82 | ACAD lower |
| PEG as of 2026-08-03 | 2.28 | -19.70 | ALKS lower |
| Net margin as of 2026-08-03 | +34.3% | +9.8% | ACAD higher |
| Gross margin as of 2026-08-03 | +91.5% | +86.6% | ACAD higher |
| Operating margin as of 2026-08-03 | +7.4% | +12.3% | ALKS higher |
| ROE as of 2026-08-03 | +35.6% | +8.8% | ACAD higher |
| ROA as of 2026-08-03 | +26.2% | +5.4% | ACAD higher |
| Debt / equity as of 2026-08-03 | 0.00 | 0.86 | ACAD lower |
| Revenue growth (YoY) as of 2026-08-03 | -13.6% | +3.2% | ALKS higher |
| Revenue CAGR (3y) SEC XBRL | +27.5% | +9.9% | ACAD higher |
| Beta as of 2026-08-03 | 0.89 | 0.26 | |
| 1-year return as of 2026-07-31 close | +8.6% | +101.8% | ALKS higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.